←
Andy Biotech9,943 posts
Andy Biotech avatar

Andy Biotech

@AndyBiotech

#Biotech Investor | Recovering Scientist | May have L/S position in names mentioned | Opinions are strictly my own and not intended as investment advice

◷ Joined July 2012▧ 3,673 Photos and videos
Andy Biotech avatar
Andy Biotech@AndyBiotech·8 Dec 2023

Amazing to see translational science is moving at a much faster pace in #biotech these days from bench to bedside! #CRISPR 11yrs 2012 Doudna/Charpentier paper 2020 Nobel 2023 First FDA approval $CRSP #RNAi 20yrs 1998 Fire/Mello paper 2006 Nobel 2018 First FDA approval $ALNY

Andy Biotech avatar
Andy Biotech@AndyBiotech·18 Sep 2023

End of an era! As a long-time follower of global #biotech/healthcare, I have learned a lot from the many good analysts at @CreditSuisse esp for their ex-US coverage, which was often more critical than typical US sell-side coverage. Best wishes to everyone on their new endeavor!

Post attachment
Andy Biotech avatar
Andy Biotech@AndyBiotech·22 Jun 2023

$SRPT ELEVIDYS priced at $3.2M This is probably the biggest problem w/ accelerated approvals for the healthcare system. How does it make sense that a drug under AA w/ unproven benefits priced 50% higher than $NVS Zolgensma at $2.1M w/ full approval and established efficacy?

Andy Biotech avatar
Andy Biotech@AndyBiotech·12 Jun 2023

"The exception is more interesting than the rule." #Biotech reverse merger occasionally turn into >$1B buyout Aduro➡️ $KDNY ➡️$3.2B $NVS shell➡️Medivation➡️$14B $PFE Trimeris➡️Synageva➡️$8.4B ALXN CancerVax➡️Micromet➡️$1.2B $AMGN Biodel➡️Albireo➡️$1B Ipsen shell➡️Cougar➡️$1B JNJ

Andy Biotech avatar
Andy Biotech@AndyBiotech·7 Jun 2023

As expected, FDA AdCom on $BIIB/Eisai lecanemab is setting up to be a "clearing the air" event after the whole Aduhelm saga. More importantly, FDA reviewer made it very clear the changes observed on the CDR-SB is considered "clinically meaningful".

Post attachment

$BIIB My thought on lecanemab "clinical meaningfulness" debate: 18-mo rx slowed disease progression by 6~8mo. Is it not meaningful to pts and families to have 6~8 more months of your memory and freedom? An oncology drug w/ 6~8mo of PFS benefit would be heralded as breakthrough!

Post attachment
Andy Biotech avatar
Andy Biotech@AndyBiotech·16 May 2023

Friendly reminder: "Don't talk about something you don't know much about as if you understand it. People in the field can tell."

Making it even harder for $KDNY atrasentan to get FDA approval is a competing drug, sparsentan, has exclusive orphan drug approval. Atrasentan would have to show it is more efficacious and/or safer. Comparing trial data, atrasentan seems to be inferior muddywatersresearch.com/rese…

Andy Biotech avatar
Andy Biotech@AndyBiotech·12 May 2023

$SRPT FDA summary slides today emphasizes the key point that "Patients likely have only one chance to receive an AAV vector-based gene therapy for DMD", which could drive the panel discussion today to wait for Ph3 data that will be available later this year.

Post attachmentPost attachment
Andy Biotech avatar
Andy Biotech@AndyBiotech·10 May 2023

$SRPT Apparently FDA placed SRP-9001 on clinical hold in Aug 2021 due to an unexpected SAE of asthenia requiring hospitalization and respiratory support, but the company never disclosed it to investors AFAIK. Did it not count as a material event for most important pipeline drug?

Post attachment
Andy Biotech avatar
Andy Biotech@AndyBiotech·3 May 2023

Overall great news for #Alzheimer pts! Another unequivocally positive Ph3 should further validate Aβ MoA, bolster doctor confidence and derisk CMS reimbursement. $LLY comment to STAT about curve widening over time provides further evidence for the promise of "disease modifying"

This tweet is unavailable

Andy Biotech avatar
Andy Biotech@AndyBiotech·13 Mar 2023

$SNY continues its quest as biotech shorties' worst enemy $3.3B $PRVB at 273% premium ahead of first earning after launch $2.5B $THOR at 172% premium before PoC -> IL2 discontinued + $1.7B impairment $3.7B $PRNB -> clinical hold due to DILI $3.2B $TBIO -> COVID19 discontinued

Andy Biotech avatar
Andy Biotech@AndyBiotech·19 Jan 2023

$BIIB/Eisai lecanemab KO $LLY Donanemab in Round 1 of #Alzheimer's new drug fight FDA Issues Complete Response Letter for Accelerated Approval of Donanemab due to limited number of patients with 12-month drug exposure

Andy Biotech avatar
Andy Biotech@AndyBiotech·12 Dec 2022

$HZNP Cheers for an early Christmas gift! $145M River Vision acq turned out to be one of the best deals in biotech history: Pharmacyclics -> Celera for ibrutinib Vertex -> $538M Aurora for CF franchise Gilead -> $470M Triangle for HIV franchise JAZZ -> $122M Orphan Med for Xyrem

$HZNP to acquire River Vision for $145M. Congrats @bmgallagherjr! globenewswire.com/news-relea… Nice data in NEJM last wk

Andy Biotech avatar
Andy Biotech@AndyBiotech·30 Nov 2022

$BIIB My thought on lecanemab "clinical meaningfulness" debate: 18-mo rx slowed disease progression by 6~8mo. Is it not meaningful to pts and families to have 6~8 more months of your memory and freedom? An oncology drug w/ 6~8mo of PFS benefit would be heralded as breakthrough!

Post attachment